AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Genomics Topic Track

The potential of genomic analysis to define disease and disease risk as well as health is still being elucidated. From practical sessions highlighting current testing strategies to an overview of the emerging field of epigenetics, attendees will see how this fast-moving field is progressing.


Beyond Single-Gene Analysis: Paving the Way to Comprehensive Tumor
Genomic Profiling 32219

Developed in cooperation with the College of American Pathologists and the AACC Molecular Pathology Division.

The design and implementation of multitargeted molecular testing in clinical practice is an area of great interest, with consideration of both sequential single-gene testing algorithms and parallel multiplexed assays. This course is ideal for practitioners within the field of cancer pathology, with an emphasis on molecular diagnostics. Presenters will share their experiences using targeted genotyping assays in lung cancer, colon cancer, thyroid cancer, and melanoma, as well as with the PROFILE™ initiative, an effort to provide multiplexed genetic analysis of all cancer samples. The speakers also will offer insight into the keys to success and potential pitfalls to avoid in establishing a broad tumor-genotyping platform in an academic center.

Moderator: Neal Lindeman, Brigham and Women's Hospital, Boston, MA.

Speakers: Method/Platform Selection and Integration with Core Pathology, Lynette Sholl, MD, Brigham & Women's Hospital, Boston, MA; Primary and Secondary Germline Cancer Susceptibility Testing Using MSK-IMPACT, Diana Mandelker, PhD, Memorial Sloan Kettering Cancer Center, New York, NY.


Plenary Session: The Epigenetic Basis of Common Human Disease 13001

Epigenetics is a branch of science that studies the biochemical modifications of the genome. Dr. Andrew Feinberg has made fundamental discoveries in the field of epigenetics, impacting diverse fields ranging from cancer, stem cells, molecular diagnostics and novel therapeutics. He was the first to uncover evidence for methylation-mediated reversible behavior in a whole organism. Dr. Feinberg also has made important discoveries involving altered DNA methylation in human cancer, human imprinted genes, and loss of imprinting in cancer, and the molecular basis of Beckwith-Wiedemann syndrome and epigenetic risk of cancer. Most recently, he pioneered genome-scale epigenetics (epigenomics), with the first whole-genome bisulfite sequencing analysis of human cancer, and the discovery of large hypomethylated blocks, as well as a mechanism for disrupting these blocks in epithelial-mesenchymal transition. He has shown the close relationship between epigenomics changes in normal development, cancer, and stem cell reprogramming. This lecture will explore epigenetic mechanisms on normal development, cancer, and stem cell reprogramming and discuss its exciting implications for molecular diagnostics as well as novel forms of therapy.

Speaker: Andrew Feinberg, MD, MPH, Johns Hopkins University, Baltimore, MD.

Meet the Expert: The Epigenetic Basis of Common Human Disease 63101

This session provides an excellent opportunity for a limited number of attendees to meet with Dr. Andrew Feinberg, a world authority on epigenetics. Dr. Feinberg has made fundamental discoveries in epigenetics, impacting multiple fields. He will discuss epigenetic changes in normal development, cancer, and stem cell reprogramming, and their implications for molecular diagnostics and novel forms of therapy.

Speaker: Andrew Feinberg, MD, MPH, Johns Hopkins University, Baltimore, MD.